Seer, a San Francisco based life sciences company capturing insights from the proteome, announced a $55 million Series D round led by aMoon Fund. This funding comes one year after Seer announced their $36 million venture round to come out of stealth, and brings total funding to over $100 million.
Seer uses high-speed, high-accuracy proteomic analysis with their Proteograph™ platform to enable insights and understanding of biology and diseases. The resulting data complements genomic and other health data to answer clinical challenges, such as disease detection at early stages. Seer's second patent application was also published recently.
